Literature DB >> 30056038

Reproducibility of data-driven Parkinson's disease subtypes for clinical research.

Tiago A Mestre1, Shirley Eberly2, Caroline Tanner3, David Grimes4, Anthony E Lang5, David Oakes2, Connie Marras5.   

Abstract

INTRODUCTION: PD subtype classification systems attempt to address heterogeneity in PD, a widely recognized feature of the disease with implications in prognosis and therapeutic development. There is no consensus on a valid PD subtype classification system, and its use in clinical research is sparse. Reproducibility has not been systematically assessed as a step for the validation of a PD subtype classification system. We aimed at assessing reproducibility of previously published data-driven PD subtype classification systems in a well-characterized cohort created for clinical research purposes, the Longitudinal and Biomarker Study in Parkinson's Disease (LABS-PD).
METHODS: We identified all published studies of data-driven PD subtype classification systems and included those with variables that conceptually matched the variables available in LABS-PD. We reproduced the cluster analyses of the included studies in LABS-PD. Reproducibility was determined by a panel of experts using a modified Delphi consensus process.
RESULTS: We included eight studies of data-driven PD subtype classification systems and completed the replication in LABS-PD of the analyses conducted in each original study. After two iterations of the modified Delphi consensus process, no study was reproducible in LABS-PD.
CONCLUSIONS: Currently published data-driven PD subtype classification systems lack reproducibility in a well-characterized cohort of patients initially recruited for a clinical trial of a disease-modifying intervention. The results raise concerns about the utility of the widely-discussed concept of data-driven PD subtypes. This gap is a barrier for a meaningful use of PD subtypes and calls for the establishment of standards for the validation and use of these subtype classification systems.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Clinical subtypes; Data-driven; Delphi technique; Heterogeneity; Parkinson disease; Reproducibility

Mesh:

Substances:

Year:  2018        PMID: 30056038     DOI: 10.1016/j.parkreldis.2018.07.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  Parkinson's disease motor subtype changes during 20 years of follow-up.

Authors:  Robert S Eisinger; Daniel Martinez-Ramirez; Adolfo Ramirez-Zamora; Christopher W Hess; Leonardo Almeida; Michael S Okun; Aysegul Gunduz
Journal:  Parkinsonism Relat Disord       Date:  2019-05-19       Impact factor: 4.891

2.  Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.

Authors:  Lauren E Ryden; Simon J G Lewis
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

Review 3.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 4.  Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Authors:  Alberto J Espay; Lorraine V Kalia; Ziv Gan-Or; Caroline H Williams-Gray; Philippe L Bedard; Steven M Rowe; Francesca Morgante; Alfonso Fasano; Benjamin Stecher; Marcelo A Kauffman; Matthew J Farrer; Chris S Coffey; Michael A Schwarzschild; Todd Sherer; Ronald B Postuma; Antonio P Strafella; Andrew B Singleton; Roger A Barker; Karl Kieburtz; C Warren Olanow; Andres Lozano; Jeffrey H Kordower; Jesse M Cedarbaum; Patrik Brundin; David G Standaert; Anthony E Lang
Journal:  Neurology       Date:  2020-02-26       Impact factor: 9.910

Review 5.  Subtyping of Parkinson's Disease - Where Are We Up To?

Authors:  Elizabeth Qian; Yue Huang
Journal:  Aging Dis       Date:  2019-10-01       Impact factor: 6.745

Review 6.  Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer.

Authors:  Marie-Louise Zeissler; Vivien Li; Mahesh K B Parmar; Camille Buchholz Carroll
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

7.  Association of specific biotypes in patients with Parkinson disease and disease progression.

Authors:  Linbo Wang; Wei Cheng; Edmund T Rolls; Fuli Dai; Weikang Gong; Jingnan Du; Wei Zhang; Shouyan Wang; Fengtao Liu; Jian Wang; Peter Brown; Jianfeng Feng
Journal:  Neurology       Date:  2020-08-14       Impact factor: 9.910

8.  Progressive brain atrophy and clinical evolution in Parkinson's disease.

Authors:  Massimo Filippi; Elisabetta Sarasso; Noemi Piramide; Tanja Stojkovic; Iva Stankovic; Silvia Basaia; Andrea Fontana; Aleksandra Tomic; Vladana Markovic; Elka Stefanova; Vladimir S Kostic; Federica Agosta
Journal:  Neuroimage Clin       Date:  2020-08-07       Impact factor: 4.881

9.  Unsupervised clustering of dopamine transporter PET imaging discovers heterogeneity of parkinsonism.

Authors:  Minseok Suh; Jin Hee Im; Hongyoon Choi; Han-Joon Kim; Gi Jeong Cheon; Beomseok Jeon
Journal:  Hum Brain Mapp       Date:  2020-08-05       Impact factor: 5.038

Review 10.  Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management.

Authors:  Xylena Reed; Artur Schumacher-Schuh; Jing Hu; Sara Bandres-Ciga
Journal:  J Pers Med       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.